US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu ...

Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...

Sotyktu (deucravacitinib) is a brand-name oral tablet that’s prescribed for plaque psoriasis in certain adults. As with other drugs, Sotyktu can cause side effects. These include cancer and ...

The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu, and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $ ...

Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...

Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult ...

Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment ...

(RTTNews) - Bristol Myers Squibb (BMY) announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to ...